A Phase 2 interventional study of D-aspartate and Placebo in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 17 sites in Italy. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-02-10.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Merck KGaA, Darmstadt, Germany.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 2, and was the 37th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 200 across the 21 interventional studies, 150 across the 19 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
Dietary Supplement: D-aspartate · Biological: IFN beta-1a · Drug: Methylprednisolone
Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
Drug: Placebo · Biological: IFN beta-1a · Drug: Methylprednisolone
D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Time frame: Baseline, Week 8
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Time frame: Baseline, Week 12 and 24
25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
Time frame: At Week 8, 12 and 24
9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome.
Time frame: At Week 8, 12 and 24
Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome.
Time frame: Week 8, 12 and 24
Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold \[RMT\]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome.
Time frame: Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8
Number of Treated Participants With Immune-metabolic Response of Lymphocytes
Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported.
Time frame: Baseline, Week 8 and 12
| Milestone | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Started | 5 | 2 |
| Completed | 4 | 1 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
| Participants | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8 | 1 | 0 |
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
| Participants | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Week 12 | 1 | 0 |
| Week 24 | 1 | 0 |
The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
| Seconds | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Participant 1: Trial 1: Week 8 | 13.1 | — |
| Participant 1: Trial 2: Week 8 | 12.4 | — |
| Participant 2: Trial 1: Week 8 | 12.7 | — |
| Participant 2: Trial 2: Week 8 | 12.6 | — |
| Participant 3: Trial 1: Week 8 | 17.4 | — |
| Participant 3: Trial 2: Week 8 | 16.3 | — |
| Participant 4: Trial 1: Week 8 | 11.3 | — |
| Participant 4: Trial 2: Week 8 | 10.9 | — |
| Participant 5: Trial 1: Week 8 | 5.6 | — |
| Participant 5: Trial 2: Week 8 | 5.7 | — |
| Participant 6: Trial 1: Week 8 | — | 16.1 |
| Participant 6: Trial 2: Week 8 | — | 14.3 |
| Participant 7: Trial 1: Week 8 | — | 9.3 |
| Participant 7: Trial 2: Week 8 | — | 8.9 |
| Participant 1: Trial 1: Week 12 | 13.1 | — |
| Participant 1: Trial 2: Week 12 | 13.8 | — |
| Participant 3: Trial 1: Week 12 | 17.1 | — |
| Participant 3: Trial 2: Week 12 | 15.8 | — |
| Participant 4: Trial 1: Week 12 | 10.9 | — |
| Participant 4: Trial 2: Week 12 | 10.2 | — |
| Participant 5: Trial 1: Week 12 | 5.7 | — |
| Participant 5: Trial 2: Week 12 | 5.6 | — |
| Participant 6: Trial 1: Week 12 | — | 12.7 |
| Participant 6: Trial 2: Week 12 | — | 12.3 |
| Participant 7: Trial 1: Week 12 | — | 12.4 |
| Participant 7: Trial 2: Week 12 | — | 11.8 |
| Participant 1: Trial 1: Week 24 | 11.8 | — |
| Participant 1: Trial 2: Week 24 | 11.5 | — |
| Participant 3: Trial 1: Week 24 | 8.6 | — |
| Participant 3: Trial 2: Week 24 | 9.3 | — |
| Participant 4: Trial 1: Week 24 | 11.4 | — |
| Participant 4: Trial 2: Week 24 | 11.5 | — |
| Participant 5: Trial 1: Week 24 | 5.0 | — |
| Participant 5: Trial 2: Week 24 | 5.3 | — |
| Participant 7: Trial 1: Week 24 | — | 10.1 |
| Participant 7: Trial 2: Week 24 | — | 9.8 |
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome.
| Seconds | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Participant 1: Trial 1: Week 8: Dominant hand | 22.1 | — |
| Participant 1: Trial 2: Week 8: Dominant hand | 21.1 | — |
| Participant 2: Trial 1: Week 8: Dominant hand | 18.7 | — |
| Participant 2: Trial 2: Week 8: Dominant hand | 17.6 | — |
| Participant 3: Trial 1: Week 8: Dominant hand | 19.7 | — |
| Participant 3: Trial 2: Week 8: Dominant hand | 16.3 | — |
| Participant 4: Trial 1: Week 8: Dominant hand | 17.8 | — |
| Participant 4: Trial 2: Week 8: Dominant hand | 17.2 | — |
| Participant 5: Trial 1: Week 8: Dominant hand | 22.6 | — |
| Participant 5: Trial 2: Week 8: Dominant hand | 25.5 | — |
| Participant 6: Trial 1: Week 8: Dominant hand | — | 17.5 |
| Participant 6: Trial 2: Week 8: Dominant hand | — | 17.2 |
| Participant 7: Trial 1: Week 8: Dominant hand | — | 31.9 |
| Participant 7: Trial 2: Week 8: Dominant hand | — | 9.5 |
| Participant 1: Trial 1: Week 12: Dominant hand | 24.2 | — |
| Participant 1: Trial 2: Week 12: Dominant hand | 22.0 | — |
| Participant 3: Trial 1: Week 12: Dominant hand | 17.6 | — |
| Participant 3: Trial 2: Week 12: Dominant hand | 17.8 | — |
| Participant 4: Trial 1: Week 12: Dominant hand | 16.8 | — |
| Participant 4: Trial 2: Week 12: Dominant hand | 16.1 | — |
| Participant 5: Trial 1: Week 12: Dominant hand | 25.3 | — |
| Participant 5: Trial 2: Week 12: Dominant hand | 23.2 | — |
| Participant 6: Trial 1: Week 12: Dominant hand | — | 21.1 |
| Participant 6: Trial 2: Week 12: Dominant hand | — | 17.9 |
| Participant 7: Trial 1: Week 12: Dominant hand | — | 31.6 |
| Participant 7: Trial 2: Week 12: Dominant hand | — | 29.8 |
| Participant 1: Trial 1: Week 24: Dominant hand | 22.0 | — |
| Participant 1: Trial 2: Week 24: Dominant hand | 21.5 | — |
| Participant 3: Trial 1: Week 24: Dominant hand | 18.8 | — |
| Participant 3: Trial 2: Week 24: Dominant hand | 18.1 | — |
| Participant 4: Trial 1: Week 24: Dominant hand | 17.2 | — |
| Participant 4: Trial 2: Week 24: Dominant hand | 16.7 | — |
| Participant 5: Trial 1: Week 24: Dominant hand | 27.4 | — |
| Participant 5: Trial 2: Week 24: Dominant hand | 24.6 | — |
| Participant 7: Trial 1: Week 24: Dominant hand | — | 32.6 |
| Participant 7: Trial 2: Week 24: Dominant hand | — | 30.8 |
| Participant 1: Trial 1: Week 8: Non-Dominant hand | 25.2 | — |
| Participant 1: Trial 2: Week 8: Non-Dominant hand | 25.3 | — |
| Participant 2: Trial 1: Week 8: Non-Dominant hand | 18.9 | — |
| Participant 2: Trial 2: Week 8: Non-Dominant hand | 17.3 | — |
| Participant 3: Trial 1: Week 8: Non-Dominant hand | 21.4 | — |
| Participant 3: Trial 2: Week 8: Non-Dominant hand | 20.7 | — |
| Participant 4: Trial 1: Week 8: Non-Dominant hand | 18.9 | — |
| Participant 4: Trial 2: Week 8: Non-Dominant hand | 19.7 | — |
| Participant 5: Trial 1: Week 8: Non-Dominant hand | 22.0 | — |
| Participant 5: Trial 2: Week 8: Non-Dominant hand | 20.8 | — |
| Participant 6: Trial 1: Week 8: Non-Dominant hand | — | 19.5 |
| Participant 6: Trial 2: Week 8: Non-Dominant hand | — | 19.9 |
| Participant 7: Trial 1: Week 8: Non-Dominant hand | — | 22.0 |
| Participant 7: Trial 2: Week 8: Non-Dominant hand | — | 21.1 |
| Participant 1: Trial 1: Week 12: Non-Dominant hand | 22.8 | — |
| Participant 1: Trial 2: Week 12: Non-Dominant hand | 19.8 | — |
| Participant 3: Trial 1: Week 12: Non-Dominant hand | 20.8 | — |
| Participant 3: Trial 2: Week 12: Non-Dominant hand | 22.5 | — |
| Participant 4: Trial 1: Week 12: Non-Dominant hand | 17.3 | — |
| Participant 4: Trial 2: Week 12: Non-Dominant hand | 17.5 | — |
| Participant 5: Trial 1: Week 12: Non-Dominant hand | 22.8 | — |
| Participant 5: Trial 2: Week 12: Non-Dominant hand | 23.7 | — |
| Participant 6: Trial 1: Week 12: Non-Dominant hand | — | 20.6 |
| Participant 6: Trial 2: Week 12: Non-Dominant hand | — | 20.4 |
| Participant 7: Trial 1: Week 12: Non-Dominant hand | — | 24.5 |
| Participant 7: Trial 2: Week 12: Non-Dominant hand | — | 25.7 |
| Participant 1: Trial 1: Week 24: Non-Dominant hand | 22.4 | — |
| Participant 1: Trial 2: Week 24: Non-Dominant hand | 20.5 | — |
| Participant 3: Trial 1: Week 24: Non-Dominant hand | 20.1 | — |
| Participant 3: Trial 2: Week 24: Non-Dominant hand | 18.4 | — |
| Participant 4: Trial 1: Week 24: Non-Dominant hand | 18.1 | — |
| Participant 4: Trial 2: Week 24: Non-Dominant hand | 18.3 | — |
| Participant 5: Trial 1: Week 24: Non-Dominant hand | 25.8 | — |
| Participant 5: Trial 2: Week 24: Non-Dominant hand | 22.7 | — |
| Participant 7: Trial 1: Week 24: Non-Dominant hand | — | 24.1 |
| Participant 7: Trial 2: Week 24: Non-Dominant hand | — | 23.6 |
Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome.
| units on a scale | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Participant 1: Week 8 | 38 | — |
| Participant 2: Week 8 | 43 | — |
| Participant 3: Week 8 | 48 | — |
| Participant 4: Week 8 | 66 | — |
| Participant 5: Week 8 | 46 | — |
| Participant 6: Week 8 | — | 56 |
| Participant 7: Week 8 | — | 43 |
| Participant 1: Week 12 | 48 | — |
| Participant 3: Week 12 | 44 | — |
| Participant 4: Week 12 | 68 | — |
| Participant 5: Week 12 | 44 | — |
| Participant 6: Week 12 | — | 46 |
| Participant 7: Week 12 | — | 43 |
| Participant 1: Week 24 | 50 | — |
| Participant 3: Week 24 | 51 | — |
| Participant 4: Week 24 | 70 | — |
| Participant 5: Week 24 | 39 | — |
| Participant 7: Week 24 | — | 55 |
Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome.
| Letters read correctly | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Participant 1: Week 8: Left eye | 4 | — |
| Participant 2: Week 8: Left eye | 8 | — |
| Participant 3: Week 8: Left eye | 8 | — |
| Participant 4: Week 8: Left eye | 8 | — |
| Participant 6: Week 8: Left eye | — | 8 |
| Participant 7: Week 8: Left eye | — | 8 |
| Participant 1: Week 12: Left eye | 2 | — |
| Participant 3: Week 12: Left eye | 10 | — |
| Participant 4: Week 12: Left eye | 8 | — |
| Participant 6: Week 12: Left eye | — | 8 |
| Participant 7: Week 12: Left eye | — | 9 |
| Participant 1: Week 24: Left eye | 3 | — |
| Participant 3: Week 24: Left eye | 10 | — |
| Participant 4: Week 24: Left eye | 10 | — |
| Participant 7: Week 24: Left eye | — | 8 |
| Participant 1: Week 8: Right eye | 4 | — |
| Participant 2: Week 8: Right eye | 8 | — |
| Participant 3: Week 8: Right eye | 2 | — |
| Participant 4: Week 8: Right eye | 7 | — |
| Participant 6: Week 8: Right eye | — | 8 |
| Participant 7: Week 8: Right eye | — | 8 |
| Participant 1: Week 12: Right eye | 8 | — |
| Participant 3: Week 12: Right eye | 10 | — |
| Participant 4: Week 12: Right eye | 7 | — |
| Participant 6: Week 12: Right eye | — | 8 |
| Participant 7: Week 12: Right eye | — | 9 |
| Participant 1: Week 24: Right eye | 8 | — |
| Participant 3: Week 24: Right eye | 10 | — |
| Participant 4: Week 24: Right eye | 10 | — |
| Participant 7: Week 24: Right eye | — | 8 |
MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome.
| units on a scale | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Participant 1: Week 8 | 8 | — |
| Participant 2: Week 8 | 27 | — |
| Participant 3: Week 8 | 15 | — |
| Participant 4: Week 8 | 2 | — |
| Participant 5: Week 8 | 18 | — |
| Participant 6: Week 8 | — | 27 |
| Participant 7: Week 8 | — | 29 |
| Participant 1: Week 12 | 6 | — |
| Participant 3: Week 12 | 12 | — |
| Participant 4: Week 12 | 12 | — |
| Participant 5: Week 12 | 15 | — |
| Participant 6: Week 12 | — | 27 |
| Participant 7: Week 12 | — | 30 |
| Participant 1: Week 24 | 10 | — |
| Participant 3: Week 24 | 48 | — |
| Participant 4: Week 24 | 12 | — |
| Participant 5: Week 24 | 15 | — |
| Participant 7: Week 24 | — | 43 |
Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome.
| units on a scale | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Participant 1: Week 8 | 1.2 | — |
| Participant 2: Week 8 | 2.6 | — |
| Participant 3: Week 8 | 1.7 | — |
| Participant 4: Week 8 | 1.1 | — |
| Participant 5: Week 8 | 1 | — |
| Participant 6: Week 8 | — | 4.3 |
| Participant 7: Week 8 | — | 2.2 |
| Participant 1: Week 12 | 1.3 | — |
| Participant 3: Week 12 | 2.6 | — |
| Participant 4: Week 12 | 2 | — |
| Participant 5: Week 12 | 1 | — |
| Participant 6: Week 12 | — | 4.1 |
| Participant 7: Week 12 | — | 4.1 |
| Participant 1: Week 24 | 1.3 | — |
| Participant 3: Week 24 | 2.8 | — |
| Participant 4: Week 24 | 2 | — |
| Participant 5: Week 24 | 1.1 | — |
| Participant 7: Week 24 | — | 3.3 |
TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold \[RMT\]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome.
| millivolts | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Participants 1: Week 8 (Baseline): 110% RMT | 30 | — |
| Participants 1: Week 8 (Baseline): 120% RMT | 105 | — |
| Participants 1: Week 8 (Baseline): 130% RMT | 142 | — |
| Participants 1: Week 8 (Post-baseline): 110% RMT | 39 | — |
| Participants 1: Week 8 (Post-baseline): 120% RMT | 128 | — |
| Participants 1: Week 8 (Post-baseline): 130% RMT | 154 | — |
| Participants 3: Week 8 (Baseline): 110% RMT | 23 | — |
| Participants 3: Week 8 (Baseline): 120% RMT | 95 | — |
| Participants 3: Week 8 (Baseline): 130% RMT | 115 | — |
| Participants 3: Week 8 (Post-baseline): 110% RMT | 31 | — |
| Participants 3: Week 8 (Post-baseline): 120% RMT | 103 | — |
| Participants 3: Week 8 (Post-baseline): 130% RMT | 118 | — |
| Participants 6: Week 8 (Baseline): 110% RMT | — | 28 |
| Participants 6: Week 8 (Baseline): 120% RMT | — | 83 |
| Participants 6: Week 8 (Baseline): 130% RMT | — | 118 |
| Participants 6: Week 8 (Post-baseline): 110% RMT | — | 26 |
| Participants 6: Week 8 (Post-baseline): 120% RMT | — | 91 |
| Participants 6: Week 8 (Post-baseline): 130% RMT | — | 125 |
| Participants 7: Week 8 (Baseline): 110% RMT | — | 33 |
| Participants 7: Week 8 (Baseline): 120% RMT | — | 140 |
| Participants 7: Week 8 (Baseline): 130% RMT | — | 149 |
| Participants 7: Week 8 (Post-baseline): 110% RMT | — | 30 |
| Participants 7: Week 8 (Post-baseline): 120% RMT | — | 135 |
| Participants 7: Week 8 (Post-baseline): 130% RMT | — | 138 |
Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported.
No measurements were reported for this outcome.
Collected over Baseline up to 292 days; Participants were assessed for adverse events for the entire study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| D-aspartate + IFN Beta-1a + Methylprednisolone | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Placebo + IFN Beta-1a + Methylprednisolone | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone |
|---|---|---|
| Flu-like symptomsInfections and infestations | 1/5 | 1/2 |
| Periorbital painEye disorders | 0/5 | 1/2 |
| HypersexualityReproductive system and breast disorders | 1/5 | 0/2 |
| Weight gainGeneral disorders | 1/5 | 0/2 |
| Pain in the left thighGeneral disorders | 1/5 | 0/2 |
| Age, Categorical(Participants) | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 2 | 7 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone | Total |
|---|---|---|---|
| Female | 2 | 0 | 2 |
| Male | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | D-aspartate + IFN Beta-1a + Methylprednisolone | Placebo + IFN Beta-1a + Methylprednisolone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 2 | 7 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Jan 2019, 9 months.
Results were first posted in Feb 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting →
Merck KGaA, Darmstadt, Germany →